



Kurma Partners announces the successful IPO of Orphazyme, a leading company in rare diseases which raises €80M on Nasdaq Copenhagen

On Thursday November 16th, Orphazyme A/S (Orphazyme) initiated its first trading day on Nasdaq Copenhagen, Denmark. The IPO was several times oversubscribed and the company market capitalization was circa €214M (1, 594 million DKK) at an initial pricing of 80 DKK per share. Kurma acted as lead investor of Orphazyme series B financing in January 2015 through an investment of its Kurma Biofund II vehicle.

Rémi Droller, Managing Partner at Kurma Partners comments : “ Orphazyme’s IPO is one of the most successful IPO for Biotech in Europe with 80M€ raised before the 15% overallotment option, this is a great achievement which confirms the potential of Orphazyme to become a frontrunner in the development of a new generation of treatment for rare diseases caused by misfolding or aggregation of proteins “

About Orphazyme

Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. The Company was founded in 2009 based on early scientific discovery in heat shock proteins (“HSPs”). Since inception, the Company has translated scientific discovery into a late stage clinical development programme. The Company is headquartered in Copenhagen and currently has 30 employees. The Company focuses on severe and mostly fatal diseases with a high unmet need, and with a particularly strong commitment to neuromuscular diseases and a group of severe genetic diseases called lysosomal storage diseases. The Company plans to pursue development of its lead candidate through to registration in the EU and the United States after which launch and commercialisation is expected to be undertaken by the Company. The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis (“sIBM”) and Amyotrophic Lateral Sclerosis (“ALS”), and two lysosomal storage diseases, Niemann Pick type C (“NPC”) and Gaucher disease.

About Kurma Partners

Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.

www.kurmapartners.com

Press contacts: NewCap - Nicolas Merigeau: [+33\(0\)1 44 71 94 98](tel:+330144719498) – nmerigeau@newcap.fr